Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
OTLKW was delisted on the 16th of February, 2022.
7 hedge funds and large institutions have $122K invested in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
69% less capital invested
Capital invested by funds: $395K → $122K (-$273K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$4.67K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Ionic Capital Management
New York
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAM
1
Cormorant Asset Management
Boston,
Massachusetts
| $46K | – | – | – |
|
|
PA
2
Perceptive Advisors
New York
| $46K | – | – | – |
|
|
MWNA
3
Marshall Wace North America
New York
| $14K | – | – | – |
|
|
PC
4
PointState Capital
New York
| $11K | – | – | – |
|
|
MIM
5
Monashee Investment Management
Boston,
Massachusetts
| $3K | +$4.67K | +25,000 | New |
|
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $2K | +$3.68K | +19,743 | New |
|
|
ICM
7
Ionic Capital Management
New York
| – | -$6K | -17,826 | Closed |
|
OTLKW Hedge Fund Activity: Q2 2019 in Review
7 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) for Q2 2019, worth a combined $122K — down 69% from $395K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new OTLKW positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Monashee Investment Management, opening a new position worth an estimated $4.67K. The largest seller was Ionic Capital Management, exiting entirely with an estimated $6K sold.
- 7 institutional investors held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) as of Q2 2019, up from 6 in Q1 2019.
- Funds reported $122K of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 stock for Q2 2019, down 69% quarter-over-quarter.
- 2 funds opened new Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 positions in Q2 2019 and 1 closed out, a net change of +1 holder.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 buyer in Q2 2019 was Monashee Investment Management, an estimated $4.67K added.
- The largest Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 seller in Q2 2019 was Ionic Capital Management, an estimated $6K sold.
Based on aggregated 13F filings for Q2 2019.